You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

 

Online download statistics by month:

Online download statistics by month: April 2021 to June 2025

AbstractFullPdf
Apr 2021501502194
May 2021351351118
Jun 202131631679
Jul 202121321396
Aug 202116116148
Sep 202116216258
Oct 202119819864
Nov 202121921868
Dec 202119719748
Jan 202219719954
Feb 202216717459
Mar 202221822277
Apr 202225225678
May 202225626681
Jun 202221822354
Jul 202221121269
Aug 202222322670
Sep 202227828387
Oct 202224124979
Nov 202224925165
Dec 202220520566
Jan 202325025366
Feb 202322122376
Mar 202320120264
Apr 202321621760
May 202313914350
Jun 202314714741
Jul 202316717058
Aug 202313413429
Sep 202310110230
Oct 202311411435
Nov 202315315338
Dec 202325125135
Jan 2024848642
Feb 202410310341
Mar 202418518785
Apr 202415815860
May 202419819967
Jun 202413813861
Jul 202433233549
Aug 202412412345
Sep 202413313368
Oct 202414915074
Nov 202412512761
Dec 202415215338
Jan 202514915038
Feb 202512112152
Mar 202511311372
Apr 202514914967
May 2025757580
Jun 2025484929
Total966397423223